依普利酮通过阻断Kv1.3通道调控Treg细胞外泌体miRNA信号抑制心肌纤维化的分子机制
批准号:
81960661
项目类别:
地区科学基金项目
资助金额:
35.0 万元
负责人:
程路峰
依托单位:
学科分类:
心脑血管药物药理
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
程路峰
中文摘要
调节性T细胞(Tregs)为重要抗炎细胞,在抑制免疫反应、维持机体免疫自适应平衡等方面具有重要生理意义,其主要分泌抗炎细胞因子IL-10和促纤维化因子TGF-β。免疫细胞因子可促进心肌纤维化(MF),但有报道Tregs通过分泌IL-10能逆转MF。我们前期发现Tregs明显促进共培养的心肌成纤维细胞(CFs)增殖,胞内外TGF-β的增加明显高于IL-10的增加;而Tregs Kv1.3通道可被醛固酮受体拮抗剂eplerenone直接阻断或RNAi沉默则抑制Tregs活化,减少TGF-β分泌,抑制CFs增殖。外泌体携带miRNAs在细胞通讯中发挥重要作用,我们已证实Tregs来源的外泌体可促CFs增殖达84%。本研究拟过表达/沉默/抑制剂干预Kv1.3通道,高通量测序外泌体miRNA表达谱,明确差异miRNAs在Tregs促MF的中介作用,为抗MF提供免疫学新途径,为新药靶点研究奠定基础。
英文摘要
Regulatory T cell (Tregs) is an important anti-inflammatory cell, which plays an important role in inhibiting immune response and maintaining immune adaptive balance. It mainly secretes anti-inflammatory cytokine IL-10 and pro-fibrotic factor TGF-β. Immune cytokines can promote myocardial fibrosis (MF), but it has been reported that Tregs can reverse MF by secreting IL-10. Previously we found that Tregs significantly promoted the proliferation of co-cultured cardiac fibroblasts (CFs), and the increase of TGF-β was significantly higher than that of IL-10 whatever in extracellular or intracellular environments, meanwhile the Tregs Kv1.3 channels could be inhibited by eplerenone, an aldosterone antagonist directly or silenced through RNAi, to suppress the activation of Tregs, and decreased the secretion of TGF-β, so that to restrain the proliferation of CFs. Exosome carrying miRNAs exerts a crucial role in cell communication. We have confirmed that Tregs-derived exosome can facilitate CFs proliferation up to 84%. In this study, we plan to overexpress/silence/inhibit Kv1.3 channels, to conduct high-throughput sequencing of expression profile on the exosome miRNA, to clarify the mediating role of differential miRNAs in promoting MF by Tregs. It will provide a new immunologic approach for anti-MF, and lay a foundation for new drug target exploitation.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:
--
发表时间:
2022
期刊:
中国新药与临床杂志
影响因子:
作者:
[张雍正, 武洋, 李梦佳, 程路峰]
通讯作者:
程路峰
DOI:
10.3390/ijms232012565
发表时间:
2022-10-19
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[]
通讯作者:
依善利酮抑制Kv1.3通道抗1型糖尿病的双重调节机制
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:0万元
-
批准年份:2024
-
负责人:程路峰
-
依托单位:
依普利酮抑制Kv1.3通道抗1型糖尿病的双重调节机制
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:32万元
-
批准年份:2024
-
负责人:程路峰
-
依托单位:
醛固酮受体拮抗剂基于慢性心衰时T细胞Kv1.3通道的Th17/Treg平衡免疫调节机制
-
批准号:81360491
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2013
-
负责人:程路峰
-
依托单位:
国内基金
海外基金